Iris Garrido-Cano

10PUBLICATIONS
19CO-AUTHORS
Molecular targetsPsychosocial aspects of childbirth and perinatal mental healthGene and molecular therapyNanometrologyMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 10, 2026
Fibroblast Activation Protein Alpha-Targeted Nanoparticles for Tumor Microenvironment Remodeling and Antitumor Therapy in Triple-Negative Breast Cancer.

Ana Lameirinhas, Paula Díez, Francisco J Hicke

|Apr 10, 2025
Deciphering the transcriptomic landscape of early HR+/HER2- breast cancer in very young women.

Iris Garrido-Cano, Marta Tapia, Juan Carbonell

|Aug 22, 2024
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.

Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas

|Sep 28, 2023
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.

Marta Tapia, Cristina Hernando, María Teresa Martínez

|Aug 07, 2023
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy.

Iris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas

|Feb 25, 2023
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.

Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano

Pageof 2

Frequent Collaborators

4 joint publications

Pilar Eroles

3 joint publications

Cristina Hernando

2 joint publications

Ana Lameirinhas

2 joint publications

Ana Lluch